Australia - English - Department of Health (Therapeutic Goods Administration)

upjohn australia pty ltd - pregabalin -

Australia - English - Department of Health (Therapeutic Goods Administration)

upjohn australia pty ltd - eletriptan hydrobromide -

Australia - English - Department of Health (Therapeutic Goods Administration)

upjohn australia pty ltd - eletriptan hydrobromide -

Australia - English - Department of Health (Therapeutic Goods Administration)

upjohn australia pty ltd - eletriptan hydrobromide -

Australia - English - Department of Health (Therapeutic Goods Administration)

upjohn australia pty ltd - eletriptan hydrobromide -

Australia - English - Department of Health (Therapeutic Goods Administration)

upjohn australia pty ltd - ziprasidone hydrochloride monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

upjohn australia pty ltd - ziprasidone hydrochloride monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

upjohn australia pty ltd - ziprasidone hydrochloride monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

upjohn australia pty ltd - ziprasidone hydrochloride monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 250 mg - tablet, uncoated - excipient ingredients: purified water; docusate sodium; gelatin; sodium benzoate; magnesium stearate; sodium starch glycollate; macrogol 400; isopropyl alcohol; maize starch; microcrystalline cellulose - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.